Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $14.59 and last traded at $14.72, with a volume of 542,419 shares. The stock had previously closed at $15.13.
Analyst Ratings Changes
SRPT has been the subject of a number of research reports. Weiss Ratings raised Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday. Benchmark reiterated a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, September 9th. Zacks Research lowered shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, October 5th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, September 28th. Finally, Robert W. Baird set a $18.00 price objective on shares of Sarepta Therapeutics in a research note on Friday, November 6th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have assigned a Sell rating to the stock. According to data from MarketBeat, Sarepta Therapeutics has an average rating of “Hold” and an average target price of $23.67.
Check Out Our Latest Report on SRPT
Sarepta Therapeutics Trading Down 2.3%
The firm has a market cap of $1.58 billion, a price-to-earnings ratio of -10.79, a PEG ratio of 0.38 and a beta of 0.45. The company has a fifty day moving average price of $18.44 and a 200-day moving average price of $18.48. The company has a current ratio of 3.46, a quick ratio of 2.13 and a debt-to-equity ratio of 0.46.
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $381.35 million for the quarter, compared to the consensus estimate of $352.20 million. Sarepta Therapeutics had a negative return on equity of 0.20% and a negative net margin of 5.86%. The company’s revenue was down 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.13) earnings per share. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current year.
Institutional Investors Weigh In On Sarepta Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new stake in Sarepta Therapeutics during the second quarter worth $27,000. Pinnacle Wealth Planning Services Inc. grew its position in Sarepta Therapeutics by 50.6% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,780 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 598 shares during the period. Nykredit A S purchased a new position in Sarepta Therapeutics in the second quarter valued at $43,000. Ancora Advisors LLC purchased a new position in Sarepta Therapeutics in the second quarter valued at $45,000. Finally, Allworth Financial LP acquired a new position in shares of Sarepta Therapeutics in the second quarter worth about $58,000. Institutional investors and hedge funds own 86.68% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.
Read More
- Five stocks we like better than Sarepta Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
